Pfizer’s covid-19 vaccine candidate Shows Promise in Test As Global cases top 10.5m

Patent waiver seen stalling vaccine production in Nigeria

COVAX has secured enough vaccines to achieve 45 percent of coverage across countries by the middle of this year

An early trial of an experimental coronavirus vaccine from Pfizer Inc. and BioNtech SE showed it’s safe and prompted patients to produce antibodies against the new virus, keeping it in the lead pack for a pandemic shot. The messenger RNA product was tested on 45 healthy adults divided in several

```

Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```